Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | BCR | P11274 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 2/20 | 0.45 |
| ▸ | AURKA | O14965 | 5/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5479137 | 0.86 | AURKA (0.59) | SYKAURKAHPGDBTK | |
| SCHEMBL5474518 | 0.78 | SYK (0.52) | SYKAURKANPC1ALDH1A1RAB9A | |
| SCHEMBL13337389 | 0.75 | SYK (0.68) | SYKBTK | |
| SCHEMBL5478616 | 0.72 | HPGD (0.45) | HPGDNPC1ALDH1A1RAB9AHSD17B10 | |
| SCHEMBL5483237 | 0.72 | EPHB4 (0.45) | ABL1BCRHPGDNPC1RAB9A | |
| SCHEMBL19322178 | 0.71 | NPC1 (0.56) | HPGDNPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL6222200 | 0.71 | EPHB4 (0.69) | AURKAEPHB4 | |
| SCHEMBL3788827 | 0.71 | SYK (0.70) | SYK | |
| SCHEMBL4810983 | 0.71 | BTK (0.81) | SYKAURKAEPHB4BTK | |
| SCHEMBL3800925 | 0.70 | SYK (0.74) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919340-B2 | Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof | CELLULAR GENOMICS, INC. (US) | 2005-07-19 | — | — | US | claimed |
| EP-1509526-A2 | IMIDAZO(1,2-A)PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF | Cellular Genomics Inc. (US) | 2005-03-02 | — | — | EP | claimed |
| US-20030212073-A1 | Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof | GILEAD CONNECTICUT, INC. | 2003-11-13 | — | — | US | claimed |
| WO-2003089434-A2 | IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES METHOD OF MAKING AND METHOD OF USE THEREOF | CELLULAR GENOMICS, INC. (US) | 2003-10-30 | — | — | WO | claimed |
| US-20050288295-A1 | Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. | 2005-12-29 | — | — | US | disclosed |
| US-6919340-B2 | Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof | CELLULAR GENOMICS, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| WO-2005047290-A2 | IMIDAZO[1,2-A] PYRAZIN-8-YLAMINES AS KINASE INHIBITORS | CELLULAR GENOMICS INC. (US) | 2005-05-26 | — | — | WO | disclosed |
| EP-1509526-A2 | IMIDAZO(1,2-A)PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF | Cellular Genomics Inc. (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20030212073-A1 | Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof | GILEAD CONNECTICUT, INC. | 2003-11-13 | — | — | US | disclosed |
| WO-2003089434-A2 | IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES METHOD OF MAKING AND METHOD OF USE THEREOF | CELLULAR GENOMICS, INC. (US) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212073-A1 | Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof | PRKACA, MAP3K8, MAP3K1 | ABL1 82/4885BCR 2105/4885SYK 705/4885 |
| US-20050288295-A1 | Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof | MAP3K8, MAP3K1, PRKACA | ABL1 192/4885BCR 952/4885SYK 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.